


Searching News Database: nebivolol
HSMN NewsFeed - 22 Jul 2013
Forest Laboratories, Inc. Announces Additional Settlement Agreement in BYSTOLIC(R) Patent Litigation
Forest Laboratories, Inc. Announces Additional Settlement Agreement in BYSTOLIC(R) Patent Litigation
HSMN NewsFeed - 23 Feb 2010
Forest Laboratories Receives Decision from FDA for Supplemental New Drug Application for Bystolic(R)
Forest Laboratories Receives Decision from FDA for Supplemental New Drug Application for Bystolic(R)
HSMN NewsFeed - 12 Sep 2008
CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
HSMN NewsFeed - 27 Feb 2008
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
HSMN NewsFeed - 18 Dec 2007
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
HSMN NewsFeed - 2 Dec 2007
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
HSMN NewsFeed - 1 May 2007
Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol
Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol
Additional items found! 12
Members Archive contains
12 additional stories matching:
nebivolol
(Password required)
nebivolol
(Password required)
